A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours

Therapuetic Areas:Oncology
Age Range:18 - Any
Start Date:November 21, 2016
End Date:September 30, 2020
Contact:Boehringer Ingelheim Call Center

Use our guide to learn which trials are right for you!

An Open-label, Phase I Trial to Determine the Maximum-tolerated Dose and Investigate Safety, Pharmacokinetics, and Efficacy of BI 754091 in Patients With Advanced Solid Tumours

The main objective of the dose-escalation part of the trial is to determine the safety and
tolerability, and to determine the Maximum Tolerated Dose and/or the Recommended Phase 2 Dose
(RP2D) of BI 754091 on the basis of patients with dose-limiting toxicities (DLTs) in patients
with selected advanced solid malignancies. Safety and tolerability will be evaluated by
monitoring the occurrence of adverse events (AEs), serious AEs (SAE), and laboratory
parameter abnormalities, as well as changes to vital signs.

Secondary objectives are the determination of the PK profile of BI 754091 after single and
multiple doses of BI 754091, and the preliminary assessment of antitumour activity.

In the dose-expansion part of the trial, the main objectives are to further assess the
safety, efficacy, PK profile, and biomarkers of BI 754091 in tumours with specific tumour
types and/or genetic mutations at the RP2D.

Inclusion Criteria:

- Provision of signed and dated, written Informed Consent Form (ICF) prior to any
trial-specific procedures, sampling, or analyses. If a patient declines to participate
in the voluntary pharmacogenetics component of the trial, he/she will not be excluded
from other aspects of the trial.

- Patients ≥18 years of age at the time of signature of the ICF

- Phase Ia (dose-escalation)

- patients with a histologically confirmed diagnosis of advanced, unresectable,
and/or metastatic solid tumours (any type).

- patients who have received all therapy known to confer clinical benefit
(including anti-PD-1 or anti-PDL1 therapies, if relevant), or for whom no therapy
of proven efficacy exists, or who are not amenable to standard therapies.
Patients with anti- PD-1 or anti-PDL1 experience must have a minimum of 60 days
between the last dose of the previous anti PD-1/PD-L1 and Cycle 1 Day 1 of BI
754091 treatment.

- Patients may agree to provide optional paired biopsies.

- Phase Ib (dose expansion)

- patients with a histologically confirmed diagnosis of select advanced,
unresectable, and/or metastatic solid tumours with specific histology/tumour
types and/or specific genetic profiles

- All patients must have measurable lesions according to Response Evaluation
Criteria in Solid Tumours (RECIST) v1.1 must have at least 1 tumour lesion
amenable to biopsy, and must be medically fit and willing to undergo a biopsy
before first treatment and, unless clinically contraindicated, after 6 weeks on

- patients who are anti-PD-1 and anti-PDL-1naïve but have failed conventional
treatment (excluding anti-PD-1 treatment), or for whom no therapy of proven
efficacy exists, or who are not amenable to standard therapies.

- Eastern Cooperative Oncology Group (ECOG) score: 0 to 1

- Life expectancy of at least 12 weeks after the start of the treatment according to the
Investigator's judgement

- Females of child-bearing potential willing to use adequate contraceptive measures from
the time of screening until 6 months after trial discontinuation, who are not or will
not be breast feeding, and agree to have pregnancy tests prior to the start of dosing
and at regular visits during the trial. Females not of childbearing potential must
have evidence of such by fulfilling one of the following criteria at screening:

- Post-menopausal: defined as more than 50 years-of-age and amenorrhoeic for at
least 12 months following cessation of all exogenous hormonal treatments

- Documentation of irreversible surgical sterilization by hysterectomy, bilateral
oophorectomy, or bilateral salpingectomy

- Women under 50 years-of-age would be considered postmenopausal if they have been
amenorrhoeic for at least 12 months following the cessation of exogenous hormonal
treatments, and have serum follicle-stimulating hormone and luteinizing hormone
levels in the postmenopausal range for the institution.

- For women of childbearing potential using a contraceptive pill, an additional
barrier method is necessary. Acceptable highly effective methods of contraception
include total sexual abstinence when this is in line with the preferred and usual
lifestyle of the study participant (periodic abstinence such as calendar,
ovulation, symptothermal, post-ovulation methods and withdrawal are not
acceptable methods of contraception), an intrauterine device or intrauterine
hormone-releasing system, bilateral tubal ligation, and vasectomised partner
(with post-vasectomy proof of absence of sperm)

- Further inclusion criteria apply

Exclusion criteria:

- Major surgery (major according to the Investigator's assessment) performed within 12
weeks prior to first trial treatment or planned within 12 months after screening,
e.g.,hip replacement

- Patients who must or wish to continue the intake of restricted medications or any drug
considered likely to interfere with the safe conduct of the trial

- Previous enrolment in this trial

- Any investigational or anti-tumour treatment within 4 weeks or 5 half-life period
(whichever is shorter) prior to the initial administration of BI 754091.

- Presence of other active invasive cancers other than the one treated in this trial
within 5 years prior to screening, with the exception of appropriately treated
basal-cell carcinoma of the skin, in situ carcinoma of the uterine cervix, or other
local tumours considered cured by local treatment.

- Untreated brain metastasis(es) that may be considered active. Patients with previously
treated brain metastases may participate provided they are stable (i.e., without
evidence of Progression of Disease by imaging for at least 4 weeks prior to the first
dose of trial treatment, and any neurologic symptoms have returned to baseline), and
there is no evidence of new or enlarging brain metastases

- Inadequate organ function or bone marrow reserve as demonstrated by the following
laboratory values:

- Absolute neutrophil count <1.5 x 10^9/L (<1500/mm3)

- Platelet count <100 x 10^9/L

- Haemoglobin <90 g/L (<9 g/dL)

- Alanine aminotransferase (ALT) >2.5 times the upper limit of normal (ULN) if no
demonstrable liver metastases or >5 times ULN in the presence of liver metastases

- Aspartate aminotransferase (AST) >2.5 times ULN if no demonstrable liver
metastases or >5 times ULN in the presence of liver metastases

- Total bilirubin >1.5 times ULN, except for patients with Gilbert's syndrome who
are excluded if total bilirubin >3.0 x ULN or direct bilirubin >1.5 x ULN

- Creatinine >1.5 times ULN or creatinine clearance <50 mL/min (measured or
calculated by Chronic Kidney Disease Epidemiology (CKD-EPI) Collaboration
equation); confirmation of creatinine clearance is only required when creatinine
is >1.5 times ULN.

- Any of the following cardiac criteria:

- Mean resting corrected QT interval (QTc) >470 msec

- Any clinically important abnormalities (as assessed by the Investigator) in
rhythm, conduction, or morphology of resting Electrocardiograms, e.g., complete
left bundle branch block, third degree heart block

- Any factors that increase the risk of QTc prolongation or risk of arrhythmic
events such as heart failure, hypokalaemia, congenital long QT syndrome, family
history of long QT syndrome or unexplained sudden death under 40 years-of-age, or
any concomitant medication known to prolong the QT interval

- Ejection fraction (EF) <55% or the lower limit of normal of the institutional
standard will be excluded. Only in cases where the Investigator (or the treating
physician or both) suspects cardiac disease with negative effect on the EF will
the EF be measured during screening using an appropriate method according to
local standards to confirm eligibility (e.g., echocardiogram [ECHO], multi-gated
acquisition scan [MUGA]). A historic measurement of EF no older than 6 months
prior to first administration of study drug can be accepted provided that there
is clinical evidence that the EF value has not worsened since this measurement in
the opinion of the Investigator or of the treating physician or both.

- History of pneumonitis within the last 5 years

- History of severe hypersensitivity reactions to other monoclonal Antibodies

- Immunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within
4 weeks prior to the first dose of BI 754091

- Active autoimmune disease or a documented history of autoimmune disease, except
vitiligo or resolved childhood asthma/atopy

- Known history of human immunodeficiency virus infection or an active hepatitis B or C
virus infection. HIV infection is allowed for patients in cohort 6 (cervical/anal
squamous) and cohort 7 (vulvar)

- Interstitial lung disease

- Chronic alcohol or drug abuse or any condition that, in the Investigator's opinion,
makes him/her an unreliable trial subject, unlikely to complete the trial, or unable
to comply with the protocol procedures.
We found this trial at
1 Ingalls Dr
Harvey, Illinois 60426
(708) 333-2300
Ingalls Memorial Hospital As the area's only independent not-for-profit healthcare system, Ingalls has the ability...
Harvey, IL
Click here to add this to my saved trials
Detroit, Michigan 48201
Detroit, MI
Click here to add this to my saved trials
Click here to add this to my saved trials
250 25th Ave N, Ste 100
Nashville, Tennessee 37023
Tennessee Oncology, PLLC Since 1976 Tennessee Oncology has been providing quality cancer care. In 2013,...
Nashville, TN
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73104
Oklahoma City, OK
Click here to add this to my saved trials
Sarasota, Florida 34232
Sarasota, FL
Click here to add this to my saved trials